In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.

Kenya, being the first nine countries globally selected to roll out Lenacapavir, a long-acting injectable HIV prevention drug, starting January 2026. The National AIDS and STI Control Programme ...

“It’s estimated that over 10 million people around the world develop Alzheimer’s disease annually,” said UVA Health researcher Jayakrishna Ambati, MD. “Our results suggest that taking these drugs ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Oct 30 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, ...

LONDON (Reuters) - GlaxoSmithKline scrapped plans to float its HIV drug business on Wednesday and promised to pay a steady dividend for three years, setting out long-term growth targets after the ...